Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.76 |
| ▸ | SLC10A2 | Q12908 | 12/20 | 0.35 |
| ▸ | CTSD | P07339 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16415717 | 1.00 | NR1H4 (0.76) | NR1H4SLC10A2CTSD | |
| SCHEMBL5743635 | 0.96 | NR1H4 (0.83) | NR1H4SLC10A2 | |
| SCHEMBL25249701 | 0.94 | NR1H4 (0.77) | NR1H4SLC10A2CTSD | |
| SCHEMBL4732517 | 0.93 | NR1H4 (0.74) | NR1H4SLC10A2CTSD | |
| SCHEMBL5691778 | 0.93 | NR1H4 (0.74) | NR1H4SLC10A2CTSD | |
| SCHEMBL6049392 | 0.92 | NR1H4 (0.73) | NR1H4SLC10A2CTSD | |
| SCHEMBL5407206 | 0.92 | NR1H4 (0.80) | NR1H4SLC10A2 | |
| SCHEMBL5793707 | 0.92 | NR1H4 (0.80) | NR1H4SLC10A2 | |
| SCHEMBL5142403 | 0.92 | NR1H4 (0.76) | NR1H4SLC10A2CTSD | |
| SCHEMBL5843738 | 0.91 | NR1H4 (0.64) | NR1H4SLC10A2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3777864-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | Albireo AB (SE) | 2021-02-17 | — | — | EP | claimed |
| EP-3400944-B1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2020-07-15 | — | — | EP | claimed |
| US-20200069715-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | LUMENA PHARMACEUTICALS LLC (US) | 2020-03-05 | — | — | US | claimed |
| US-10555950-B2 | Bile acid recycling inhibitors for treatment of obesity and diabetes | SATIOGEN PHARMACEUTICALS, INC. (US) | 2020-02-11 | — | — | US | claimed |
| EP-3400944-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | Albireo AB (SE) | 2018-11-14 | — | — | EP | claimed |
| EP-3023102-B1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2018-06-27 | — | — | EP | claimed |
| US-20160193277-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2016-07-07 | — | — | US | claimed |
| US-20160194353-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2016-07-07 | — | — | US | claimed |
| EP-3023102-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | Albireo AB (SE) | 2016-05-25 | — | — | EP | claimed |
| US-9339480-B2 | Bile acid recycling inhibitors for treatment of obesity and diabetes | SATIOGEN PHARMACEUTICALS, INC. (US) | 2016-05-17 | — | — | US | claimed |
| EP-2771003-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | Lumena Pharmaceuticals, Inc. (US) | 2014-09-03 | — | — | EP | claimed |
| US-20140243281-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | Lumena Pharmaceuticals, Inc. (US) | 2014-08-28 | — | — | US | claimed |
| EP-2637667-A1 | IBAT INHIBITORS FOR TREATMENT OF METABOLIC DISORDERS AND RELATED CONDITIONS | Albireo AB (SE) | 2013-09-18 | — | — | EP | claimed |
| US-20130236541-A1 | PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER | ALBIREO AB (SE) | 2013-09-12 | — | — | US | claimed |
| US-20130225511-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | ALBIREO AB (SE) | 2013-08-29 | — | — | US | claimed |
| US-20130109671-A1 | Bile Acid Recycling Inhibitors for Treatment of Pediatric Cholestatic Liver Diseases | Lumena Pharmaceuticals, Inc. (US) | 2013-05-02 | — | — | US | claimed |
| US-20130108573-A1 | Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease | Lumena Pharmaceuticals, Inc. (US) | 2013-05-02 | — | — | US | claimed |
| WO-2013063512-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | LUMENA PHARMACEUTICALS, INC (US) | 2013-05-02 | — | — | WO | claimed |
| WO-2013063526-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2013-05-02 | — | — | WO | claimed |
| WO-2012064268-A1 | IBAT INHIBITORS FOR TREATMENT OF METABOLIC DISORDERS AND RELATED CONDITIONS | ALBIREO AB (SE) | 2012-05-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194353-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | GPR119, SLC10A1, SLC10A2 | NR1H4 46/4885SLC10A2 3/4885CTSD 2620/4885 |
| US-20130109671-A1 | Bile Acid Recycling Inhibitors for Treatment of Pediatric Cholestatic Liver Diseases | SLC10A1, SLC10A2, ABCB11 | NR1H4 4/4885SLC10A2 2/4885CTSD 877/4885 |
| US-20160193277-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | GPR119, SLC10A1, SLC10A2 | NR1H4 46/4885SLC10A2 3/4885CTSD 2620/4885 |
| US-20140243281-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SLC10A1, SLC10A2, ABCB11 | NR1H4 4/4885SLC10A2 2/4885CTSD 1207/4885 |
| US-20130225511-A1 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | GPR119, SLC10A1, SLC10A2 | NR1H4 46/4885SLC10A2 3/4885CTSD 2620/4885 |
| US-10555950-B2 | Bile acid recycling inhibitors for treatment of obesity and diabetes | SLC10A1, SLC10A2, ABCB11 | NR1H4 5/4885SLC10A2 2/4885CTSD 1112/4885 |
| US-20200069715-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SLC10A1, SLC10A2, ABCB11 | NR1H4 4/4885SLC10A2 2/4885CTSD 877/4885 |
| US-20130108573-A1 | Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease | SLC10A1, SLC10A2, ABCB11 | NR1H4 4/4885SLC10A2 2/4885CTSD 1470/4885 |
| US-20130236541-A1 | PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER | SLC10A2, GIPR, GPBAR1 | NR1H4 8/4885SLC10A2 1/4885CTSD 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.